Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00654836 · ClinicalTrials.gov registry record · Phase 2
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
A Phase 2 study, sponsored by Loyola University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00654836 is a Phase 2 study that has completed, run by Loyola University. The registered enrollment target is 32 participants.
The verdict
NCT00654836, a Phase 2 study, has completed, sponsored by Loyola University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving carboplatin and paclitaxel together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin and paclitaxel together with bevacizumab works in treating patients with locally recurrent or metastatic breast cancer.
Interventions
- DRUG Carboplatin
- BIOLOGICAL bevacizumab
- DRUG ABI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-10 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00654836
The ClinicalTrials.gov registry entry for NCT00654836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00654836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00654836 about?
NCT00654836 is a clinical study titled "Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor ...
What is the current status of trial NCT00654836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2007-10. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00654836?
The interventions under investigation include: Carboplatin (DRUG), bevacizumab (BIOLOGICAL), ABI-007 (DRUG).
Who is sponsoring clinical trial NCT00654836?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.